How has Monte Rosa Therapeutics, Inc.'s stock issuance proceeds changed year-over-year?

Monte Rosa Therapeutics, Inc.'s stock issuance proceeds increased by 32200.0% year-over-year, from $14K to $4.52M.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Monte Rosa Therapeutics, Inc. GLUE Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Nurix Therapeutics, Inc.NRIX

$18M—

Kymera TherapeuticsKYMR

$19.19M—

ImmunomeIMNM

$229K+7.5%

Cogent Biosciences, Inc.COGT

$5.76M+4,132%

Adaptive BiotechnologiesADPT

$5.03M-7.8%

Arcus BiosciencesRCUS

$0-100%

Other financials

Income statement

See full

Revenue$4.2M-95.0%

Operating income-$50.0M-214%

Net income-$44.5M-195%

EPS (diluted)-$0.45-179%

Balance sheet

See full

Cash & equivalents$159.9M+104%

Total debt$39.1M-6.7%

Total equity$521.9M+89.7%

Total assets$736.4M+87.3%

Cash flow

See full

Operating cash flow-$37.4M+17.9%

CapEx$1.9M+17.7%

Free cash flow-$39.2M+16.7%

Valuation

See full

Market cap$1.75B+361%

Enterprise value$1.63B+381%

P/S40.7×+38.4×

Profitability

See full

Operating margin-345.2%—

Net margin-302.6%—

FCF margin-45.8%-64.9pp

Returns & leverage

See full

Return on equity-32.6%—

Debt / equity0.1×-0.1×

Current ratio9.5×+3.9×

Where this comes from

Reported directly by Monte Rosa Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s stock issuance proceeds?: Monte Rosa Therapeutics, Inc. (GLUE) reported stock issuance proceeds of $4.52M in Q1 2026.
How has Monte Rosa Therapeutics, Inc.'s stock issuance proceeds changed year-over-year?: Monte Rosa Therapeutics, Inc.'s stock issuance proceeds increased by 32200.0% year-over-year, from $14K to $4.52M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.